Prevention of portal hypertension: From variceal development to clinical decompensation

Hepatology

Volumn 61, Issue 1, 2015, Pages 375-381

  Vorobioff, Julio D ^a   Groszmann, Roberto J ^b  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD31 ANTIGEN; CYCLOOXYGENASE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; NADOLOL; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR; PROPRANOLOL; SUPEROXIDE DISMUTASE; TIMOLOL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ALCOHOL ABSTINENCE; ANTIANGIOGENIC ACTIVITY; ASCITES; BRAIN DISEASE; CANCER PREVENTION; DECOMPENSATED LIVER CIRRHOSIS; ENDOTHELIAL DYSFUNCTION; ESOPHAGUS VARICES; GASTROINTESTINAL HEMORRHAGE; GENE OVEREXPRESSION; GENE TRANSFER; HEMODYNAMICS; HEPATITIS C; HUMAN; INTRAHEPATIC VASCULAR RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PORTOSYSTEMIC ENCEPHALOPATHY; PREPRIMARY PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIGNAL TRANSDUCTION; SPLANCHNIC BLOOD FLOW; UPREGULATION; VASCULAR RESISTANCE; VASODILATATION; ANIMAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); ESOPHAGEAL AND GASTRIC VARICES;

ANIMALS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; ESOPHAGEAL AND GASTRIC VARICES; HUMANS;

EID: 84920937512     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27249     Document Type: Review

References (40)

1. Thalheimer U, Bosch J, Burroughs AK. How to prevent varices from bleeding: shades of grey-the case for non-selective β blockers. Gastroenterology 2007;133:2029-2036.
2. Groszmann RJ, Merkel C, Dell'Era A, Merli M, Ripoll C, Vorobioff J. Pre-primary and primary prophylaxis. In: de Franchis R, ed. Portal Hypertension V. Proceedings of the Fifth Baveno International Consensus Workshop. Oxford, UK: Wiley-Blackwell 2011:59-74.
3. Groszmann RJ, Abraldes JG. Portal hypertension. From bedside to bench. J Clin Gastroenterol 2005;39:S125-S130.
4. Bosch J, Abraldes JG, Fernández M, García-Pagán JC. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 2010;53:558-567.
5. Pasarin M, Abraldes JG, Rodríguez-Villarrupla A, LaMura V, García-Pagán JC, Bosch J. Insulin resistance and liver microcirculation in a rat model of early NAFLD. J Hepatol 2011;55:1095-1102.
6. Abraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Groszmann RJ. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol 2006;290:G980-G987.
7. Abraldes JG, La Mura V, Bosch J. Statins in portal hipertensión. In: de Franchis R, ed. Portal Hypertension V. Proceedings of the Fifth Baveno International Consensus Workshop. Oxford, UK: Wiley-Blackwell 2011:199-204.
8. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-2261.
9. Braillon A, Calès P, Valla D, Geoffroy P, Lebrec D. Influence of the degree of liver failure on systemic and splanchnic hemodynamics and on response to propranolol in patients with cirrhosis. Gut 1986;27:1204-1209.
10. Groszmann RJ, Blei A, Atterbury C. Portal hypertension. In: Arias IM, Popper H, Jacoby WB, Schachter DA, Shafritz DA, eds. The Liver: Biology and Pathobiology, 2nd ed. New York: Raven Press; 1988:1147-1159.
11. D'Amico G, Garcia-Tsao G, Calès P, Escorsell A, Nevens F, Cestari R, et al. Diagnosis of portal hypertension: how and when. In: de Franchis R, ed. Portal Hypertension ΙΙΙ. Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. Oxford, UK: Blackwell Science; 2001:36-64.
12. Calès P, Oberti F, Payen JL, Naveau S, Guyader D, Blanc P, et al. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. Eur J Gastroenterol Hepatol 1999;11:741-745.
13. Vorobioff J, Groszmann RJ, Picabea E, Gamen M, Villavicencio R, Bordato J, et al. Prognostic value of hepatic venous pressure measurement in alcoholic cirrhosis: a ten year prospective study. Gastroenterology 1996;111:701-709.
14. Merkel C, Marin R, Angeli P, Zanella P, Felder M, Bernardinello E, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004;127:476-484.
15. D'Amico G. Stages classification of cirrhosis: Where do we stand?. In: de Franchis R, ed. Portal Hypertension V. Proceedings of the Fifth Baveno International Consensus Workshop. Oxford, UK: Wiley-Blackwell 2011:132-139.
16. Qamar AA, Groszmann RJ, Grace ND, Garcia-Tsao G, Burroughs AK, Bosch J. Lack of effect of non-selective beta-blockers on the hepatic venous pressure gradient (HVPG) in patients with mild portal hypertension: a tail of two studies [Abstract]. Hepatology 2010;52(Suppl. 1):1020 A.
17. Ripoll C, Groszmann RJ, García-Tsao G, Grace ND, Burroughs AK, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481-488.
18. Zipprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM, et al. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int 2012;32:1407-1414.
19. Rincón D, Lo Iacono O, Tejedor M, Hernando A, Ripoll C, Catalina MV, et al. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. Scand J Gastroent 2013;48:487-495.
20. Ripoll C, Groszmann RJ, García-Tsao G, Bosch J, Grace ND, Burroughs AK, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009;50:923-928.
21. Grace N. Patients with clinically significant portal hypertension caused by hepatitis C virus cirrhosis respond poorly to antiviral therapy. Clin Gastroenterol Hepatol 2011;9:536-538.
22. Rincon D, Ripoll C, Catalina MV, Bañares R. A look into the future: new treatments in the horizon-antiviral therapy. In: de Franchis R, ed. Portal Hypertension V. Proceedings of the Fifth Baveno International Consensus Workshop. Oxford, UK: Wiley-Blackwell 2011: 205-210.
23. Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010;51:2069-2076.
24. Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology 2012;56:1883-1992.
25. Chalasani N, Younossi Z, Lavine JF, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023.
26. O'Shea RS, Dasarathy S, McCullough AJ; and the Practice Guideline Committee of the American Association for the Study of Liver Diseases and the Practice Parameters Committee of the American College of Gastroenterology. Alcoholic Liver Disease. Hepatology 2010;51:307-328.
27. Ghany G, Strader DB, Thomas DL, Seeff LB. AASLD Practice Guidelines. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
28. Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013;59:375-382.
29. Pinzani M. Antifibrotic drugs. In: de Franchis R, ed. Portal Hypertension V. Proceedings of the Fifth Baveno International Consensus Workshop. Oxford, UK: Wiley-Blackwell 2011:211-217.
30. Lok ASF, McMahon BJ. AASLD Practice Guidelines. Chronic hepatitis B. Hepatology 2007;45:507-539.
31. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40:646-665.
32. Huet PM, Vincent C, Deslaurier J, Cotè J, Matsutami S, Boileau R, et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology 2008;135:1552-1560.
33. Falize L, Guillygomarc'h A, Perrin M, Lainé F, Guyader D, Brissot P, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006;44:472-477.
34. Simonetto DA, Shah VH, Kamath PS. Primary prophylaxis of variceal bleeding. Clin Liver Dis 2014;18:335-345.
35. Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol 2014;60:643-653.
36. Ferrarese A, Germani G, Rodriguez-Castro KI, Nadal E, Zanetto A, Bortoluzzi I, et al. Bleeding-unrelated mortality is not increased in patients with cirrhosis and ascites on treatment with β-blockers: a meta-analysis. J Hepatol 2014;60(Suppl 1):S385.
37. Lim JK, Groszmann RJ. Transient elastography for diagnosis of portal hypertension in liver cirrhosis: is there still a role for hepatic venous pressure gradient measurement? Hepatology 2007;45:1087-1090.
38. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1988;319:983-989.
39. García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010;362:2370-2379.
40. Vilar Gomez E, Sanchez Rodriguez Y, Calzadilla Bertot L, Torres Gonzalez A, Martinez Perez Y, Arus Soler E, et al. The natural history of compensated HCV-related cirrhosis: a prospective, long-term study. J Hepatol 2013;58:434-444.